64 terminated. 64 Phase 2, 11 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 64 | Terminated 64 |
| Phase 1 | 11 | Terminated 11 |
| Phase 3 | 1 | Terminated 1 |
Follow Respiratory Hypersensitivity: new trials by email Literature Review of Respiratory Hypersensitivity trials Research Report on Respiratory Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma Rocatinlimab, Placebo - Asthma | Phase 2 | Terminated | Amgen | 317 | 2024-05-24 | 2026-08-11 |
| Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy Experimental: CHF6001 3200 μg, Placebo Comparator: CHF6001 Placebo - Uncontrolled Asthma | Phase 2 | Terminated | Chiesi Farmaceutici S.p.A. | 517 | 2023-11-26 | 2025-12-18 |
| Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Amlitelimab, Placebo - Asthma | Phase 2 | Terminated | Sanofi | 335 | 2023-09-05 | 2026-10-02 |
| Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma RPT193, Placebo - Asthma | Phase 2 | Terminated | RAPT Therapeutics, Inc., a member of the GSK plc group of companies | 38 | 2023-07-05 | 2026-03-23 |
| Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA Itraconazole Powder, Placebo - ABPA | Phase 2 | Terminated | Pulmatrix Inc. | 8 | 2023-02-01 | 2024-04-02 |
| Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease ARO-MUC5AC, Placebo - Asthma, Chronic Obstructive Pulmonary Disease | Phase 1 / Phase 2 | Terminated | Arrowhead Pharmaceuticals | 78 | 2022-06-27 | 2026-09-14 |
| A Study to Evaluate the Efficacy and Safety of AK120 in the Treatment of Subjects With Moderate-to-severe Asthma AK120, Placebo - Asthma | Phase 2 | Terminated | Akeso | 1 | 2022-02-11 | 2022-10-12 |
| Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma CSJ117, Placebo - Asthma | Phase 2 | Terminated | Novartis Pharmaceuticals | 136 | 2021-09-08 | 2022-10-10 |
| A Study to Test if TEV-53275 is Effective in Relieving Asthma TEV-53275 Dose A, TEV-53275 Dose B, Placebo - Asthma | Phase 2 | Terminated | Teva Branded Pharmaceutical Products R&D, Inc. | 97 | 2021-05-04 | 2023-06-08 |
| Efficacy and Safety of Inhaled AZD1402 Administered for Four Weeks in Adults With Asthma on Medium-to-High Dose Inhaled Corticosteroids AZD1402, Placebo, Short acting beta agonist (SABA) (rescue medication) - Asthma | Phase 2 | Terminated | AstraZeneca | 72 | 2021-03-12 | 2025-08-28 |
| A Study to Test if TEV-48574 is Effective in Relieving Asthma TEV-48574, Placebo - Asthma | Phase 2 | Terminated | Teva Branded Pharmaceutical Products R&D, Inc. | 65 | 2020-10-07 | 2023-03-13 |
| Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma CSJ117, Placebo - Asthma | Phase 2 | Terminated | Novartis Pharmaceuticals | 335 | 2020-09-09 | 2024-06-20 |
| Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis PUR1900, Placebo - Allergic Bronchopulmonary Aspergillosis | Phase 2 | Terminated | Pulmatrix Inc. | 7 | 2019-07-31 | 2021-08-27 |
| Study of Efficacy and Safety of LOU064 in Inadequately Controlled Asthma Patients LOU064 100 mg, Placebo - Asthma | Phase 2 | Terminated | Novartis Pharmaceuticals | 76 | 2019-07-18 | 2021-10-11 |
| Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to < 12 Years With Asthma Fevipiprant - Asthma | Phase 2 | Terminated | Novartis Pharmaceuticals | 11 | 2019-05-01 | 2026-01-13 |
| Azithromycin Treatment for the Airway Microbiome in Asthma Azithromycin, Placebo - Asthma Chronic | Phase 2 | Terminated | University of Chicago | 17 | 2019-02-01 | 2023-08-23 |
| The Effect of PC945 on Aspergillus or Candida Lung Infections in Patients With Asthma or Chronic Respiratory Diseases PC945, Placebo - Asthma, Respiratory Candidiasis | Phase 2 | Terminated | Pulmocide Ltd | 13 | 2018-11-15 | 2020-06-12 |
| Repeat Dose Study of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD) GSK3772847, Placebo - Asthma | Phase 2 | Terminated | GlaxoSmithKline | 17 | 2018-04-18 | 2020-10-23 |
| PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD inhaled human insulin, Insulin Lispro (Humalog U-100) - Safety and Tolerability | Phase 2 | Terminated | Dance Biopharm Inc. | 40 | 2018-02-06 | 2019-09-13 |
| Safety, Tolerability and Pharmacokinetics of Oral Doses of RP3128 of Rhizen Pharmaceuticals RP3128, Placebo - Healthy Volunteers, Asthma | Phase 1 / Phase 2 | Terminated | Rhizen Pharmaceuticals SA | 57 | 2016-11-03 | 2019-10-04 |
Showing 20 of 64. Sign in to see all of them.
Asthma (57) · Rhinitis, Allergic (5) · Hypersensitivity (4) · Pulmonary Disease, Chronic Obstructive (4) · Aspergillosis, Allergic Bronchopulmonary (3) · Respiratory Sounds (3) · Status Asthmaticus (3) · Rhinitis (2) · Rhinitis, Allergic, Seasonal (2) · Airway Obstruction (1) · Airway Remodeling (1) · Alveolitis, Extrinsic Allergic (1) · Aspergillosis (1) · Bronchiectasis (1) · Bronchitis (1)
Hypersensitivity, Immediate (64) · Immune System Diseases (64) · Respiratory Tract Diseases (64) · Hypersensitivity (60) · Lung Diseases (60) · Bronchial Diseases (57) · Lung Diseases, Obstructive (57) · Pathological Conditions, Signs and Symptoms (9) · Infections (6) · Nose Diseases (6) · Otorhinolaryngologic Diseases (6) · Respiratory Tract Infections (6) · Pathologic Processes (5) · Chronic Disease (4)
Fluticasone (3) · Azithromycin (2) · Epinephrine (2) · enokizumab (2) · ligelizumab (2) · 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole (1) · ASM-024 (1) · Atorvastatin (1) · BASS2 protein, Arabidopsis (1) · Bosentan (1) · Chlorpheniramine (1) · Cholecalciferol (1) · Insulin Lispro (1) · Lansoprazole (1) · MK-0633 p-toluenesulfonate (1)
Novartis Pharmaceuticals (9) · Boehringer Ingelheim (3) · MedImmune LLC (3) · Amgen (2) · Amphastar Pharmaceuticals, Inc. (2) · GlaxoSmithKline (2) · Johns Hopkins University (2) · Laboratorios Leti, S.L. (2) · Merck Sharp & Dohme LLC (2) · Pulmatrix Inc. (2) · Teva Branded Pharmaceutical Products R&D, Inc. (2) · ALK-Abelló A/S (1) · Akeso (1) · Anergis (1) · Arrowhead Pharmaceuticals (1)
United States (42) · Canada (15) · Poland (15) · Germany (14) · United Kingdom (13) · Hungary (8) · Argentina (7) · Australia (7) · Czechia (7) · France (7) · Russia (7) · South Korea (7) · Bulgaria (6) · Italy (5) · Japan (5)
Joseph Parker, M.D. (2) · Alessio Fasano, M. D. (1) · Anne E Dixon, MD (1) · Antonio Nieto, MD PhD (1) · Chris Cabell, MD (1) · Christina D Adams, PhD (1) · David Broide, MD (1) · David Denning, FRCP, FRC Path, FIDSA, FMedSci (1)
PMID 21356110, PMID 21945511, PMID 23949578, PMID 32150492, PMID 32840597, PMID 33032168, PMID 33293212, PMID 33314326, PMID 34048641, PMID 34326185, PMID 36735745, PMID 39393433
2018 (2), 2008 (1), 2009 (1), 2014 (1), 2017 (1), 2019 (1), 2023 (1), P01AT002647 (1), R21AT004089 (1), U01HL119952 (1)